

Clinical Policy: Eltrombopag (Alvaiz, Promacta)

Reference Number: CP.PHAR.180

Effective Date: 03.01.16

Last Review Date: 02.26

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Eltrombopag (Alvaiz™, Promacta®) is a thrombopoietin receptor agonist.

FDA Approved Indication(s)

Promacta is indicated for the treatment of:

- Thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Promacta should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
- Thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Promacta should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy.
- In combination with standard immunosuppressive therapy for the first-line treatment of adults and pediatric patients 2 years and older with severe aplastic anemia.
- Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

Alvaiz is indicated for the treatment of:

- Thrombocytopenia in adult and pediatric patients 6 years and older with persistent or chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Alvaiz should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
- Thrombocytopenia in adult patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Alvaiz should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy.
- Adult patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

Limitation(s) of use:

- Promacta and Alvaiz are not indicated for the treatment of patients with myelodysplastic syndromes (MDS).
- Safety and efficacy of Promacta and Alvaiz have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that eltrombopag, Alvaiz and Promacta are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Persistent/Chronic Immune Thrombocytopenia (must meet all):

1. Diagnosis of persistent or chronic ITP (*see Appendix D*);
2. Prescribed by or in consultation with a hematologist;
3. Age is one of the following (a or b):
 - a. For eltrombopag (Promacta): ≥ 1 year;
 - b. For Alvaiz: ≥ 6 years;
4. One of the following (a or b):
 - a. Current (within 30 days) platelet count is $< 30,000/\mu\text{L}$;
 - b. Member has an active bleed;
5. Failure of a systemic corticosteroid, unless contraindicated or clinically significant adverse effects are experienced (*see Appendix B*);
6. For Promacta and Alvaiz requests, member must use eltrombopag (generic Promacta), unless contraindicated or clinically significant adverse effects are experienced;*

**For Illinois HIM requests, the step therapy requirement above does not apply to Alvaiz as of 1/1/2026 per IL HB 5395*

7. Eltrombopag (Promacta) and Alvaiz are not prescribed concurrently with rituximab, another thrombopoietin receptor agonist (e.g., Doptelet®, Mulpleta®, Nplate®), or spleen tyrosine kinase inhibitor (e.g., Tavalisse™);
8. For eltrombopag and Promacta: Request does not exceed health plan-approved quantity limit, if applicable;
9. Dose does not exceed 1 tablet per day and one of the following (a or b):
 - a. For Promacta: 75 mg per day;
 - b. For Alvaiz: 54 mg per day.

Approval duration: 12 months

B. Chronic Hepatitis C-Associated Thrombocytopenia (must meet all):

1. Diagnosis of chronic hepatitis C-associated thrombocytopenia;
2. Prescribed by or in consultation with a hematologist, hepatologist, gastroenterologist or infectious disease specialist;
3. Age ≥ 18 years;
4. Eltrombopag (Promacta) or Alvaiz will be used concomitantly with interferon-based therapy;
5. The degree of thrombocytopenia has prevented the initiation of interferon-based therapy or limited the ability to maintain interferon-based therapy;
6. Current (within 30 days) platelet count is $< 75,000/\mu\text{L}$;
7. For Promacta and Alvaiz requests, member must use eltrombopag (generic Promacta), unless contraindicated or clinically significant adverse effects are experienced;*

**For Illinois HIM requests, the step therapy requirement above does not apply to Alvaiz as of 1/1/2026 per IL HB 5395*

8. Eltrombopag (Promacta) and Alvaiz are not prescribed concurrently with another thrombopoietin receptor agonist (e.g., Doptelet, Mplate, Nplate) or spleen tyrosine kinase inhibitor (e.g., Tavalisse);
9. For eltrombopag and Promacta: Request does not exceed health plan-approved quantity limit, if applicable;
10. Dose does not exceed 2 tablets per day and one of the following (a or b):
 - a. For Promacta: 100 mg per day;
 - b. For Alvaiz: 72 mg per day.

Approval duration: 6 months

C. Severe Aplastic Anemia (must meet all):

1. Diagnosis of severe aplastic anemia;
2. Prescribed by or in consultation with a hematologist;
3. Age is one of the following (a or b):
 - a. For eltrombopag (Promacta): \geq 2 years;
 - b. For Alvaiz: \geq 18 years
4. Prescribed for one of the following (a or b):
 - a. For eltrombopag (Promacta) only: As first-line therapy in combination with immunosuppressive therapy (e.g., Atgam®, cyclosporine, cyclophosphamide);
 - b. Refractory or second-line treatment as a single agent following insufficient response to immunosuppressive therapy (e.g., Atgam, cyclosporine, cyclophosphamide);

**Prior authorization may be required for Atgam and cyclophosphamide*

5. Current (within 30 days) platelet count is $<$ 50,000/ μ L;
6. For Promacta and Alvaiz requests, member must use eltrombopag (generic Promacta), unless contraindicated or clinically significant adverse effects are experienced:
**For Illinois HIM requests, the step therapy requirement above does not apply to Alvaiz as of 1/1/2026 per IL HB 5395*
7. Eltrombopag (Promacta) and Alvaiz are not prescribed concurrently with another thrombopoietin receptor agonist (e.g., Doptelet, Mplate, Nplate) or spleen tyrosine kinase inhibitor (e.g., Tavalisse);
8. For eltrombopag and Promacta: Request does not exceed health plan-approved quantity limit, if applicable;
9. Dose does not exceed 2 tablets per day and one of the following (a or b):
 - a. For Promacta: 150 mg per day;
 - b. For Alvaiz: 108 mg per day.

Approval duration: 12 months

D. NCCN Compendium Indications (off-label) (must meet all):

1. Prescribed for one of the following (a, b, c, or d):
 - a. MDS;
 - b. Post-hematopoietic cell transplant with prolonged thrombocytopenia;
 - c. Immune effector cell (IEC)-associated hematologic toxicity (ICAHT);
 - d. Immunotherapy-related thrombocytopenia;

2. Prescribed by or in consultation with an oncologist or hematologist;
3. For MDS: Member has lower-risk MDS (IPSS-R [Very Low, Low, Intermediate]);
4. For MDS: Member has one of the following (a, b, c, or d):
 - a. Severe thrombocytopenia;
 - b. Refractory thrombocytopenia following disease progression or no response to hypomethylating agents (e.g., azacitidine, decitabine), immunosuppressive therapy (e.g., Atgam, cyclosporine), or clinical trial;
 - c. Thrombocytopenia or neutropenia and one of the following (i, ii, iii, or iv):
 - i. Age \leq 60 years with \leq 5% marrow blasts;
 - ii. Hypocellular marrows;
 - iii. Paroxysmal nocturnal hemoglobinuria (PNH) clone positivity;
 - iv. *STAT-3* mutant cytotoxic T-cell clones;
 - d. Symptomatic anemia with good probability to respond to immunosuppressive therapy;
5. For post-hematopoietic cell transplant with prolonged thrombocytopenia: Member has poor graft function;
6. For ICAHT: Member meets all of the following (a, b, and c; *see Appendix D*):
 - a. Has received or is receiving an IEC therapy;
 - b. Platelet count $< 25,000/\mu\text{L}$ (Grade 4 thrombocytopenia);
 - c. One of the following (i or ii):
 - i. ≥ 1 risk factor for ICAHT;
 - ii. Cytopenias beyond 21 days post-infusion;
7. For immunotherapy-related thrombocytopenia: Member has all the following (a, b, and c; *see Appendix D*):
 - a. Platelet count $\leq 50,000/\mu\text{L}$ (Grade 3 or Grade 4 thrombocytopenia);
 - b. Thrombocytopenia due to immune checkpoint inhibitor therapy;
 - c. Thrombocytopenia not responsive to corticosteroid treatment;
8. For Promacta and Alvaiz requests, member must use eltrombopag (generic Promacta), unless contraindicated or clinically significant adverse effects are experienced;*
**For Illinois HIM requests, the step therapy requirement above does not apply to Alvaiz as of 1/1/2026 per IL HB 5395*
9. Eltrombopag (Promacta) and Alvaiz are not prescribed concurrently with another thrombopoietin receptor agonist (e.g., Doptelet, Mplate, Nplate);
10. For eltrombopag and Promacta: Request does not exceed health plan-approved quantity limit, if applicable;
11. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*
**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

E. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):

- a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
- b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Persistent/Chronic Immune Thrombocytopenia, Chronic Hepatitis C-Associated Thrombocytopenia and Severe Aplastic Anemia (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy (*see Appendix D*);
3. Current (within the last 90 days) platelet count is < 400,000/µL;
4. For chronic hepatitis C-associated thrombocytopenia, member continues to receive interferon-based therapy;
5. For Promacta and Alvaiz*^ requests, member must use eltrombopag (generic Promacta), unless contraindicated or clinically significant adverse effects are experienced;

**For Illinois HIM requests, the step therapy requirement above does not apply to Alvaiz as of 1/1/2026 per IL HB 5395*

^For New York requests, the step therapy requirement above does not apply to Alvaiz

6. Eltrombopag (Promacta) and Alvaiz are not prescribed concurrently with another thrombopoietin receptor agonist (e.g., Doptelet, Mplate, Nplate) or spleen tyrosine kinase inhibitor (e.g., Tavalisse);
7. For persistent or chronic ITP: Eltrombopag (Promacta) and Alvaiz are not prescribed concurrently with rituximab;
8. For eltrombopag and Promacta: Request does not exceed health plan-approved quantity limit, if applicable;
9. If request is for a dose increase, new dose does not exceed the following:
 - a. For persistent or chronic ITP: 1 tablet per day and either (i or ii):
 - i. For eltrombopag (Promacta): 75 mg per day;
 - ii. For Alvaiz: 54 mg per day;
 - b. For chronic hepatitis C-associated thrombocytopenia: 2 tablets per day and either (i or ii):
 - i. For eltrombopag (Promacta): 100 mg per day;

- ii. For Alvaiz: 72 mg per day;
- c. For severe aplastic anemia: 2 tablets per day and either (i or ii):
 - i. For eltrombopag (Promacta): 150 mg per day;
 - ii. For Alvaiz: 108 mg per day.

Approval duration:**Hepatitis C-associated thrombocytopenia** – 6 months;**All other indications** – 12 months**B. NCCN Compendium Indications (off-label) (must meet all):**

- 1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Promacta or Alvaiz for a covered indication and has received this medication for at least 30 days;
- 2. Member is responding positively to therapy;
- 3. For Promacta and Alvaiz requests, member must use eltrombopag (generic Promacta), unless contraindicated or clinically significant adverse effects are experienced;*[^]

**For Illinois HIM requests, the step therapy requirement above does not apply to Alvaiz as of 1/1/2026 per IL HB 5395*

^For New York requests, the step therapy requirement above does not apply to Alvaiz

- 4. Eltrombopag (Promacta) and Alvaiz are not prescribed concurrently with another thrombopoietin receptor agonist (e.g., Doptelet, Mplate, Nplate);
- 5. For eltrombopag and Promacta: Request does not exceed health plan-approved quantity limit, if applicable;
- 6. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months**C. Other diagnoses/indications (must meet 1 or 2):**

- 1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
- 2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ANC: absolute neutrophil count
 CAR: chimeric antigen receptor
 FDA: Food and Drug Administration
 ICAHT: immune effector cell-associated hematologic toxicity
 IEC: immune effector cell
 IPSS-R: Revised International Prognostic Scoring System

ITP: chronic immune thrombocytopenia
 MDS: myelodysplastic syndromes
 PNH: paroxysmal nocturnal hemoglobinuria
 STAT-3: signal transducer and activator of transcription

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |
|-------------------------|--|--|
| Corticosteroids* | | |
| dexamethasone | <p>ITP</p> <p><u>Oral dosage:</u> <i>Adults:</i> Initially, 0.75 to 9 mg/day PO, given in 2 to 4 divided doses. Adjust according to patient response. <i>Children and adolescents:</i> 0.02 to 0.3 mg/kg/day PO or 0.6 to 9 mg/m²/day PO, given in 3 to 4 divided doses</p> <p><u>Intramuscular or intravenous dosage:</u> <i>Adults:</i> Initially, 0.5 to 9 mg/day IV or IM, given in 2 to 4 divided doses. Adjust according to patient response. <i>Children:</i> 0.02 to 0.3 mg/kg/day or 0.6 to 9 mg/m²/day IV or IM given in 3-4 divided doses. Adjust according to patient response.</p> | Dosage must be individualized and is highly variable depending on the nature and severity of the disease, route of treatment, and on patient response. |
| methylprednisolone | <p>ITP</p> <p><u>Oral dosage:</u> <i>Adults:</i> 4 to 48 mg/day PO in 4 divided doses. Adjust according to patient response. <i>Children:</i> 0.5 to 1.7 mg/kg/day PO in divided doses every 6 to 12 hrs</p> | Dosage must be individualized and is highly variable depending on the nature and severity of the disease, |

| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |
|------------------------------------|--|--|
| | <u>Intravenous dosage:</u> <i>Adults:</i> 10 to 40 mg IV every 4 to 6 hours for up to 72 hours <i>Children:</i> 0.11 to 1.6 mg/kg/day IV in 3 or 4 divided doses. | route of treatment, and on patient response. |
| prednisone | ITP <i>Adults:</i> Initially, 1 mg/kg PO once daily; however, lower doses of 5 mg/day to 10 mg/day PO are preferable for long-term treatment. | Dosage must be individualized and is highly variable depending on the nature and severity of the disease, route of treatment, and on patient response. |
| Immunosuppressive agents* | | |
| Atgam® (antithymocyte globulin) | Aplastic anemia 10 to 20 mg/kg/day IV infusion for 8 to 14 days, continuing with every-other-day dosing up to a total of 21 doses, if needed Off-label dosing: 40 mg/kg IV daily for four consecutive days in combination with cyclosporine | Varies |
| cyclosporine† (Sandimmune®) | Aplastic anemia 12 mg/kg PO daily | Varies |
| cyclophosphamide† | Aplastic anemia 45 to 50 mg/kg IV divided over 4 days | Varies |

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

**Examples of corticosteroids/immunosuppressive agents provided are not all inclusive*

†Off-label indication

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): none reported
- Boxed warning(s): risk for hepatic decompensation in patients with chronic hepatitis C and risk of hepatotoxicity

Appendix D: General Information

- Definition of persistent vs chronic ITP per the 2019 American Society of Hematology Guideline
 - Persistent ITP: ITP duration of 3-12 months
 - Chronic ITP: ITP duration of > 12 months
- Examples of positive response to therapy may include:

- For ITP or hepatitis C-associated thrombocytopenia:
 - Increase in platelet count from baseline levels;
 - Platelet count $\geq 50,000/\mu\text{L}$;
 - Reduction in clinically important bleeding events;
- For aplastic anemia: any of the following hematologic responses:
 - Platelet count $\geq 50,000/\mu\text{L}$
 - Platelet count increases to $20,000/\mu\text{L}$ above baseline or stable platelet counts with transfusion independence for a minimum of 8 weeks;
 - Hemoglobin increase $> 1.5 \text{ g/dL}$, or a reduction of ≥ 4 units of red blood cell (RBC) transfusions for 8 consecutive weeks;
 - Absolute neutrophil count (ANC) increase of 100% or an ANC increase greater than $500/\mu\text{L}$.
- MDS prognostic scoring system online calculator for IPSS-R:
https://qxmd.com/calculate/calculator_109/mds-revised-international-prognostic-scoring-system-ipss-r
- ICAHT is defined per European Hematology Association/European Society for Blood and Bone Marrow Transplantation (EHA-EBMT) consensus criteria as grade 4 thrombocytopenia (platelets $< 25,000/\mu\text{L}$) persistent for > 7 days, or that requires transfusion or growth factor dependence.
 - IEC therapies are immune-based therapies that leverage the body's immune system to combat malignancies, such as chimeric antigen receptor (CAR) T-cell therapies (e.g., Kymriah®, Yescarta®) and tumor-infiltrating lymphocyte therapy (e.g., Amtagvi®).
 - Risk factors for ICAHT include:
 - Bone marrow involvement by tumor
 - High tumor burden
 - Preexisting cytopenias
 - Preexisting inflammatory state
 - Active infection
 - Prior hematopoietic cell transplant
 - Receipt of bridging therapy
 - CAR-HEMATOTOX score of ≥ 2 (a risk-stratification tool that is helpful in ruling out patients at risk of hematotoxicity from CAR T-cell therapy)
- For immunotherapy-related thrombocytopenia, immunotherapy refers to immune checkpoint inhibitors. Immune checkpoint inhibitors comprise a class of agents that target immune cell checkpoints, such as programmed cell death-1 (PD-1; e.g., Opdivo®, Keytruda®) and PD-1 ligand (PD-L1; e.g., Tecentriq®, Bavencio®, Imfinzi®), as well as cytotoxic T-lymphocyte-associated antigen 4 (e.g., Yervoy®, Imjudo®).

V. Dosage and Administration

| Drug Name | Indication | Dosing Regimen | Maximum Dose |
|------------------------|---------------------------|---|--------------|
| Eltrombopag (Promacta) | Persistent or chronic ITP | Adults and pediatrics age ≥ 6 years: 50 mg PO QD Pediatrics age 1 to 5 years: 25 mg PO QD | 75 mg/day |

| Drug Name | Indication | Dosing Regimen | Maximum Dose |
|----------------------|---|--|--------------|
| | | Adjust to maintain platelet count \geq 50,000/ μ L. | |
| | Chronic hepatitis C-associated thrombocytopenia | 25 mg PO QD Adjust to achieve target platelet count required to initiate antiviral therapy. | 100 mg/day |
| | Severe aplastic anemia | <u>After an insufficient response to immunosuppressive therapy:</u> 50 mg PO QD Adjust to maintain platelet count \geq 50,000/ μ L. <u>For first-line treatment in combination with immunosuppressive therapy:</u> Patients \geq 12 years: 150 mg PO QD Patients 6 to 11 years: 75 mg PO QD Patients 2 to 5 years: 2.5 mg/kg PO QD Adjust to maintain platelet count \geq 50,000/ μ L. Total duration of treatment is 6 months. | 150 mg/day |
| Eltrombopag (Alvaiz) | Persistent or chronic ITP | Adults and pediatrics age \geq 6 years: 36 mg PO QD Adjust to maintain platelet count \geq 50,000/ μ L. | 54 mg/day |
| | Chronic hepatitis C-associated thrombocytopenia | 18 mg PO QD Adjust to achieve target platelet count required to initiate antiviral therapy. | 72 mg/day |
| | Severe aplastic anemia | <u>After an insufficient response to immunosuppressive therapy:</u> 36 mg PO QD Adjust to maintain platelet count \geq 50,000/ μ L. | 108 mg/day |

VI. Product Availability

| Drug Name | Availability |
|------------------------|---|
| Eltrombopag (Promacta) | Oral tablets: 12.5 mg, 25 mg, 50 mg, 75 mg (all strengths available as generic) Oral suspension: 12.5 mg, 25 mg (all strengths available as generic) |

| Drug Name | Availability |
|----------------------|---|
| Eltrombopag (Alvaiz) | Oral tablets: 9 mg, 18 mg, 36 mg, 54 mg |

VII. References

1. Alvaiz Prescribing Information. Parsippany, NJ: Teva; July 2024. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed51e463-7a03-4858-bbd2-882ce4753d5a>. Accessed October 17, 2025.
2. Promacta Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2025. Available at: https://www.novartis.com/us-en/sites/novartis_us/files/promacta.pdf. Accessed October 17, 2025.
3. Townsley DM, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. *N Engl J of Med.* Apr 2017;376(16):1540-1550.
4. Kulasekhararaj A, Cavenagh J, Dokal I, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. *Br J Haematol.* 2024;204(3):784-804.
5. Clinical Pharmacology [database online]. Philadelphia, PA: Elsevier. Updated periodically. Accessed November 18, 2025.
6. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv* (2019) 3 (23): 3829–3866.
7. Neunert CE, Arnold DM, Grace RF, et al. The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia. *Blood Adv.* 2024;8(13):3578-3582.
8. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed November 18, 2025.
9. National Comprehensive Cancer Network. Myelodysplastic Syndromes Version 1.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed November 18, 2025.
10. National Comprehensive Cancer Network. Hematopoietic growth factors Version 2.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf. Accessed November 18, 2025.
11. National Comprehensive Cancer Network. Immune Checkpoint Inhibitor-Related Toxicities - Immune Checkpoint Inhibitor-Related Toxicities Version 1.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/ici_tox.pdf. Accessed November 18, 2025.

| Reviews, Revisions, and Approvals | Date | P&T Approval Date |
|---|----------|-------------------|
| 1Q 2022 annual review: clarified definition of persistent vs chronic ITP in Appendix D per 2019 ASH guideline; for MDS removed IPSS and WPSS risk categorizations as IPSS-R is preferred per NCCN; included criteria for specific circumstances for MDS where disease progression on other agents is not necessary per NCCN; references reviewed and updated. | 11.15.21 | 02.22 |
| Template changes applied to other diagnoses/indications. | 10.03.22 | |

| Reviews, Revisions, and Approvals | Date | P&T Approval Date |
|--|----------|-------------------|
| 1Q 2023 annual review: per NCCN Compendium, for MDS added off-label indication of symptomatic anemia and its qualifiers; references reviewed and updated. | 10.31.22 | 02.23 |
| 1Q 2024 annual review: added NCCN Compendium-supported indication of prolonged thrombocytopenia post-hematopoietic cell transplant; added exclusion of concurrent thrombopoietin receptor agonist with Promacta to aplastic anemia, chronic hepatitis C-associated thrombocytopenia, and NCCN Compendium indications; for all FDA-labeled indications added exclusion of concurrent spleen tyrosine kinase inhibitor (e.g., Tavalisse™); references reviewed and updated. RT4: added Alvaiz, a new eltrombopag choline formulation. | 01.08.24 | 02.24 |
| 1Q 2025 annual review: added disclaimer that for HIM line of business Alvaiz is non-formulary; per NCCN Compendium, for MDS removed that request must be for Promacta and for MDS with symptomatic anemia removed requirement for no del(5q) and serum erythropoietin; references reviewed and updated. | 11.20.24 | 02.25 |
| Per August SDC, added redirection to eltrombopag (generic Promacta). Per September SDC, for ITP removed redirection to immune globulin if intolerant or contraindicated to systemic corticosteroid. For all indications other than hepatitis C-associated thrombocytopenia, revised initial approval duration from 6 to 12 months. | 09.23.25 | 12.25 |
| 1Q 2026 annual review: for post-hematopoietic cell transplant with prolonged thrombocytopenia, added requirement that member has poor graft function per NCCN; added NCCN-supported indications of ICAHT and immunotherapy-related thrombocytopenia; for eltrombopag and Promacta, added request does not exceed health plan-approved quantity limit, if applicable; references reviewed and updated. | 10.17.25 | 02.26 |

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or

remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.